Lundbeck
HLUN-B.CO
#2431
Rank
C$8.46 B
Marketcap
$8.86
Share price
-0.13%
Change (1 day)
32.07%
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

Revenue for Lundbeck (HLUN-B.CO)

Revenue in 2024 (TTM): C$4.04 Billion

According to Lundbeck 's latest financial reports the company's current revenue (TTM ) is C$4.16 Billion. In 2023 the company made a revenue of C$3.84 Billion an increase over the revenue in the year 2022 that were of C$3.50 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Lundbeck from 2009 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) C$4.04 B5.17%
2023 C$3.84 B9.7%
2022 C$3.50 B7.8%
2021 C$3.25 B-7.07%
2020 C$3.49 B3%
2019 C$3.39 B-11.64%
2018 C$3.84 B14.84%
2017 C$3.34 B7.41%
2016 C$3.11 B3.84%
2015 C$3.00 B9.3%
2014 C$2.74 B-4.89%
2013 C$2.88 B12.16%
2012 C$2.57 B-14.71%
2011 C$3.01 B15.7%
2010 C$2.60 B-4.64%
2009 C$2.73 B